2Siris ES,Chinese AA,Altman RD,et al.Risedronate in the treatment of Paget′s disease of bone:an open label,multicenter study.J Bone Miner Res,1998,13(6):1032-1038. 被引量：1
3Sir is ES, Chines AA, Ahman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study[J]. J B one Miner Res, 1998, 13(6) : 1 032 - 1 038. 被引量：1
4Usui T, Kawakami R, Watanabe T, et al. Sensitive determination of a novel bisphosphonate, YM 529, in plasma, urine and bone by high performance liquid chromatography with fluorescence detection[J]. J Chromatogr B, 1994, 652(1): 67-72. 被引量：1
5Kwong E, Chiu AM, McClintock SA, et al. HPLC analysis of an amino bispho sphonate in pharmaceutical formulations using postcolumn derivation and fluo recence detection [J]. J Chromatogr Sci, 1990, 28 ( 11 ) : 563 - 566. 被引量：1
7Frith JC,Monkkonen J,Auriola S,et al.The molecular mechanism of action of the anteresorptive and antiinflammatory drug clodronate:Evidence for the formation in vivo of a matabolite that inhabits bone resorption and causes osteoclast and macrophage apoptosis[J].Arthritis Rheum,2001,44(9):2201-2210. 被引量：1
8Olmos JM,De Vega T,Perera L,et al.Etidronate inhibits the production of IL-6 by Osteoblast-like cells[J].Methods Find Exp Clin Pharmacol,1999,21(8):519-522. 被引量：1
9Harris ST,Watts NB,Genant HK,et al.Effects of risedronate treatment on vertebral and novertebral fractures in women with postmenopausal osteoporosis:a randomized controlled trial[J].JAMA,1999,282 (14):1344-1352. 被引量：1
10Fogelman I,Ribot C,Smith R,et al.Risedronate reverses bone loss in postmenopausal women with low bone mass:results from a multinational,double-blind,placebo-controlled trial[J].J Clin Endocrinol Metab,2000,85(5):1895-1900. 被引量：1
